Teva Pharmaceutical Industries (TEVA) Raw Materials (2012 - 2018)

Teva Pharmaceutical Industries (TEVA) has reported Raw Materials for 7 consecutive years, with $1.3 billion the latest figure, recorded in Q4 2018.

• Quarterly Raw Materials fell 8.67% year-over-year to $1.3 billion in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.3 billion (down 8.67% YoY) and the FY2018 annual result came in at $1.3 billion, down 8.67% from the prior year.
• Raw Materials eased to $1.3 billion in Q4 2018 per TEVA's latest filing, from $1.4 billion in the prior quarter.
• Over the last five years, Raw Materials for TEVA reached as high as $1.7 billion in Q3 2016 and fell as low as $1.2 billion in Q4 2015.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2014 frame the typical range for Raw Materials.
• Annual changes were most pronounced in 2015 — Raw Materials dropped 21.67% — and 2016, when it jumped 33.89%.
• Year by year, Raw Materials stood at $1.3 billion in 2014, then decreased by 6.57% to $1.2 billion in 2015, then climbed by 15.9% to $1.4 billion in 2016, then grew by 4.98% to $1.5 billion in 2017, then retreated by 8.67% to $1.3 billion in 2018.
• According to Business Quant data, Raw Materials over the past three periods registered $1.3 billion, $1.4 billion, and $1.4 billion for Q4 2018, Q3 2018, and Q2 2018 respectively.